BI-1910

DRUG2 trials

Sponsors

Bioinvent International AB, BioInvent International AB

Conditions

Advanced solid tumorsHepatocellular CarcinomaNon Small Cell Lung CancerSolid Tumors

Phase 1

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

CompletedCTIS2022-503066-74-00

Bioinvent International ABAdvanced solid tumors

Start: 2023-12-04End: 2025-12-17Target: 186Updated: 2025-10-07

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Active, not recruitingNCT06205706

BioInvent International ABHepatocellular Carcinoma, Non Small Cell Lung Cancer, Solid Tumors

Start: 2023-12-04End: 2028-11-07Updated: 2025-09-19